Skip to main content
Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity
Published Web Location
http://europepmc.org/articles/PMC3354320?pdf=renderNo data is associated with this publication.
Abstract
Rapamycin, a specific inhibitor for mTOR complex 1, is an FDA-approved immunosuppressant for organ transplant. Recent developments have raised the prospect of using rapamycin to treat cancer or diabetes and to delay aging. It is therefore important to asse
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.